Overview and guidelines of off-label use of methotrexate in ectopic ă pregnancy: report by CNGOF

Archive ouverte

Marret, Henri | Fauconnier, Arnaud | Dubernard, Gil | Misme, Helene | Lagarce, Laurence | Lesavre, Magali | Fernandez, Hervé | Mimoun, Camille | Tourette, Claire | Curinier, Sandra | Rabishong, Benoit | Agostini, Aubert

Edité par CCSD ; Elsevier -

International audience. Our objective is to describe off-label use of methotrexate in ectopic ă pregnancy treatment using evidence based medicine. The patient group ă includes all women with a pregnancy outside the usual endometrium, or of ă unknown location. ă Method used was a Medline search on ectopic pregnancy managed using ă methotrexate treatment; evidence synthesis was done based on this ă current literature analysis. ă Level of evidence (LE) were given according to the centre for evidence ă base medicine rules. Grade was proposed for guidelines but no ă recommendation was possible as misoprostol is off label use for all the ă indications studied. ă In the absence of any contraindication, the protocol recommended for ă medical treatment of ectopic pregnancy is a single intramuscular ă injection of methotrexate (MTX) at a dosage of 1 mg/kg or 50 mg/m(2) ă (Grade A). It can be repeated once at the same dose should the hCG ă concentration not fall sufficiently. Pretreatment laboratory results ă must include a complete blood count and kidney and liver function tests ă (in accordance with its marketing authorization). ă MTX is an alternative to conservative treatment such as laparoscopic ă salpingotomy for uncomplicated tubal pregnancy (Grade A) with ă pretreatment hCG levels <= 5000 IU/1(Grade B). Expectant management is ă preferred for hCG levels < 1000 IU/I or in the process of spontaneous ă decreasing (Grade B). ă Intramuscular MTX is also recommended after the failure of surgical ă salpingotomy (Grade C) or immediately after surgery, if monitoring is ă not possible. Except in special circumstances, a local insitu ă ultrasound-guided MTX injection is not recommended for unruptured tubal ă pregnancies (Grade B). ă In situ MTX is an option for treating cervical, interstitial, or ă cesarean-scar pregnancies (Grade C).. In pregnancies of unknown location ă persisting more than 10 days in an asymptomatic woman who has an hCG ă level > 20001U/1, routine MTX treatment is an option. ă MTX is not indicated for combination with treatments such as ă mifepristone or potassium. (C) 2016 Published by Elsevier Ireland Ltd.

Consulter en ligne

Suggestions

Du même auteur

Evidence-based evaluation and expertise of methotrexate off label use in gynaecology and obstetrics: Work of the CNGOF. États des lieux et expertise de l'usage hors AMM du méthotrexate en gynécologie - Obstétrique: Travail du CNGOF

Archive ouverte | Marret, Henri | CCSD

International audience. In the absence of contraindication, methotrexate by intramuscular unique injection of 1mg/kg or 50mg/m2 is the medical treatment recommended for tubal ectopic pregnancy (EP; LE1). It can be r...

Management of endometriosis CNGOF/HAS clinical practice guidelines

Archive ouverte | Collinet, Pierre | CCSD

International audience

Operative hysteroscopy versus vacuum aspiration for incomplete spontaneous abortion (HY-PER): study protocol for a randomized controlled trial

Archive ouverte | Huchon, Cyrille | CCSD

International audience. BACKGROUND: Incomplete spontaneous abortions are defined by the intrauterine retention of the products of conception after their incomplete or partial expulsion. This condition may be managed...

Chargement des enrichissements...